Victoria Niklas
Direttore/Membro del Consiglio presso FIBROBIOLOGICS, INC.
Patrimonio netto: 87 600 $ in data 30/04/2024
Profilo
Victoria Niklas is an Independent Director at FibroBiologics, Inc. and the Chief Medical Officer at Oak Hill Bio Corp.
She was previously the Chief Medical & Scientific Officer at Prolacta Bioscience, Inc., Head-Neonatology at UCLA Health Systems, and Chief Division-Newborn Medicine at Nemours Children's Clinic, Inc. She holds a graduate degree from Harvard University, an undergraduate degree from Goucher College, and a doctorate from Harvard Medical School.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
FIBROBIOLOGICS, INC.
0.02% | 24/01/2024 | 7 500 ( 0.02% ) | 87 600 $ | 30/04/2024 |
Posizioni attive di Victoria Niklas
| Società | Posizione | Inizio |
|---|---|---|
| FIBROBIOLOGICS, INC. | Direttore/Membro del Consiglio | 08/04/2021 |
Oak Hill Bio Corp.
 Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | Direttore Tecnico/Scientifico/R&S | 01/01/2022 |
Precedenti posizioni note di Victoria Niklas
| Società | Posizione | Fine |
|---|---|---|
Prolacta Bioscience, Inc.
 Prolacta Bioscience, Inc. Pharmaceuticals: OtherHealth Technology Prolacta Bioscience, Inc. provides specialty formulations of human milk for the nutritional needs of premature and critically ill infants. Its products include Prolact+ H2MF, Prolact+4, Prolact+6, Prolact+8, Prolact+10 and Neo20. The company was founded by Elena Taggart Medo in1999 and is headquartered in Duarte, CA. | Direttore Tecnico/Scientifico/R&S | 01/01/2019 |
UCLA Health Systems
 UCLA Health Systems Hospital/Nursing ManagementHealth Services UCLA Health Systems operates hospitals. The private company is based in Los Angeles, CA and has subsidiaries in United States. The company was founded in 1955 by Benjamin J. Ansell. John Mazziotta has been the CEO of the company since 2015. | Corporate Officer/Principal | 01/01/2016 |
| Nemours Children's Clinic, Inc. | Corporate Officer/Principal | 01/01/2014 |
Formazione di Victoria Niklas
| Harvard University | Graduate Degree |
| Goucher College | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| FIBROBIOLOGICS, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Prolacta Bioscience, Inc.
Prolacta Bioscience, Inc. Pharmaceuticals: OtherHealth Technology Prolacta Bioscience, Inc. provides specialty formulations of human milk for the nutritional needs of premature and critically ill infants. Its products include Prolact+ H2MF, Prolact+4, Prolact+6, Prolact+8, Prolact+10 and Neo20. The company was founded by Elena Taggart Medo in1999 and is headquartered in Duarte, CA. | Health Technology |
UCLA Health Systems
UCLA Health Systems Hospital/Nursing ManagementHealth Services UCLA Health Systems operates hospitals. The private company is based in Los Angeles, CA and has subsidiaries in United States. The company was founded in 1955 by Benjamin J. Ansell. John Mazziotta has been the CEO of the company since 2015. | Health Services |
| Nemours Children's Clinic, Inc. | |
Oak Hill Bio Corp.
Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | Commercial Services |
- Borsa valori
- Insiders
- Victoria Niklas
